Experimental Research On A Recombinant Mycobacterium Smegmatis Therapeutic Vaccine Delivering GLS/IL-12 To Specific Target

Background:1. Having entered in the body, the vaccines can induce immune responses for the prevention or therapy of the diseases. Currently, the researches of tuberculosis therapeutic vaccines mainly focus on gene vaccine and the killed mycobacterium vaccae vaccine .2. Cellular immunity is considered as the most important defence of the host. The introcellular persistence of the Mtb.is the key reason for the latent infection. Multidrug-resistant TB is spreading. The recrudescence and relapse of the disease always occur. These compose the most difficult problems to deal with in prevention and therapy of tubculosis.3. The prognosis of mycobacterium infection is determined by the intrinsic nature of host's immune system. The patients with tuberculosis present Th2 immune response that restrains the producing of Th1 cytokines, thus the persistence of inefficiency in the cellular immunity of the host is formed. IL-12 is a so powerful cytokine of inducing Th1 immune response that a reversion from Th2 to Th1 would be occur when it was administered...